Merck's Arcoxia gets formal thumb's down from FDA

In a widely expected decision, the FDA has issued a non-approvable letter for Merck's Arcoxia, an arthritis therapy that foundered on its safety data. An FDA expert committee resoundingly rejected the therapy in April and the agency told Merck that researchers would have to clearly demonstrate that Arcoxia's benefits outweighed its risks before it could gain approval in the U.S. The therapy is approved in 63 countries and ginned $265 million in sales last year, despite its membership in the same class of drugs as Vioxx.

- read the release on the rejection
- check out the report on the decision from CNN

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.